Oral GPIIb / IIIa Antagonists: What Went Wrong?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|14|1587-1596

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.14, 2004-05, pp. : 1587-1596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on GPIIb/IIIa antagonists

By Hanson Julien   de Leval Xavier   Kolh Philippe   Supuran Claudiu   Pirotte Bernard   Dogné Jean-Michel  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1173-1188

Informa Healthcare

Access to resources Recommend Favorite

GPIIb/IIIa antagonists: the good, the bad and the not too ugly

By  

Inpharma, Vol. 1, Iss. 1616, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Bivalirudin benefit independent of GPIIb-IIIa antagonists

By  

Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

GPIIb-IIIa antagonists in ACS and renal impairment

By  

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond

By  

Current Pharmaceutical Design, Vol. 9, Iss. 28, 2003-11 ,pp. : 2317-2322

Bentham Science Publishers

Access to resources Recommend Favorite